Home › Nerve Degeneration › NCT07224490
Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease
RecruitingPhase 1
Who can join
Ages 18 to 60 · All sexes
Full eligibility criteria
Inclusion Criteria * Female (ages 18-45 years) or Male (ages 18-60 years) * No current or recent use of a medication (including hormonal replacement) that, in the opinion of a study investigator, can modulate the reproductive axis or willing to complete an appropriate washout for that particular medication and its method of administration * For women, negative serum hCG pregnancy test * For cases, diagnosis of post-covid-19 syndrome * For controls, history of prior covid infection but no diagnosis of post-covid-19 syndrome Exclusion Criteria * Any condition (medical, mental, or behavioral) that, in the opinion of a study investigator, would likely interfere with participation in/completion of the protocol or the interpretation of results * Active use of illicit drugs (not including marijuana) * For women, * Pregnant * Trying to become pregnant during protocol participation * Breast feeding * Surgical or natural menopause
About the study
The objective of this protocol is to use a case-control paradigm to compare the response to an intravenous administration of kisspeptin in individuals with and without post-covid-19 syndrome. The study subjects will receive a single bolus of kisspeptin.
What is being tested
- Kisspeptin 112-121 (drug)
Sponsor: Stephanie B. Seminara, MD · Participants: 40 · Started: Mar 10, 2026
Contact the study team
- Study Coordinator · Phone: 617-643-2308
Official record on ClinicalTrials.gov — NCT07224490
Locations in the U.S.
| Massachusetts | Massachusetts General Hospital, Boston |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.